Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

11.00 -0.22 (-1.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,150,616
Open 11.12
Bid (Size) 10.53 (1)
Ask (Size) 11.81 (1)
Prev. Close 11.22
Today's Range 10.79 - 11.34
52wk Range 9.670 - 33.06
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END 
Via FinancialNewsMedia
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results 
From Relay Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-26.86%
-26.86%
1 Month
-3.25%
-3.25%
3 Month
-33.57%
-33.57%
6 Month
-40.25%
-40.25%
1 Year
-32.43%
-32.43%

More News

Read More
Relay Therapeutics: Q1 Earnings Insights
Via Benzinga
Earnings Outlook For Relay Therapeutics
Via Benzinga
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
What 11 Analyst Ratings Have To Say About Relay Therapeutics
Via Benzinga
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
Via Benzinga
Why Relay Therapeutics Stock Is Trading Higher Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
Via Benzinga
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Relay Therapeutics Stock Is Plunging Today
Via Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
Via Benzinga
Get In Now. 7 Stocks That Are Set to Soar.
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
Via FinancialNewsMedia
Evogene Offers An Excellent Risk/Reward Ratio
Via Talk Markets
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
From Relay Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.